发布求助
文献互助 智能选刊 最新文献

Therapeutic delivery最新文献

筛选
英文 中文
Emerging nanotechnology backed formulations for the management of atopic dermatitis. 新兴的纳米技术支持治疗特应性皮炎的配方。
IF 4.2
Therapeutic delivery Pub Date : 2023-09-01 Epub Date: 2023-09-06 DOI: 10.4155/tde-2023-0033
Ranjit Kumar Mahato, Mohini Singh, Hemanta Pathak, Niva Rani Gogoi, Rikynjai Kharbithai, Pinky Chowrasia, Pankaj Lochan Bora, Tumpa Sarkar, Bani Kumar Jana, Bhaskar Mazumder
{"title":"Emerging nanotechnology backed formulations for the management of atopic dermatitis.","authors":"Ranjit Kumar Mahato, Mohini Singh, Hemanta Pathak, Niva Rani Gogoi, Rikynjai Kharbithai, Pinky Chowrasia, Pankaj Lochan Bora, Tumpa Sarkar, Bani Kumar Jana, Bhaskar Mazumder","doi":"10.4155/tde-2023-0033","DOIUrl":"10.4155/tde-2023-0033","url":null,"abstract":"<p><p>Atopic dermatitis is a prevalent chronic skin inflammation affecting 2.1 to 4.1% of adults globally. The complexity of its pathogenesis and the relapsing nature make it challenging to treat. Current treatments follow European Academy of Dermatology and Venerology guidelines, but advanced cases with recurring lesions lack effective therapies. To address this gap, researchers are exploring nanotechnology for targeted drug delivery. Nanoparticles offer benefits such as improved drug retention, stability, controlled release and targeted delivery through the disrupted epidermal barrier. This integrated review evaluates the current state of AD treatment and highlights the potential of novel nano-formulations as a promising approach to address the disease.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"543-569"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10162612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Internal stimuli-responsive nanocarriers for controlled anti-cancer drug release: a review. 内刺激反应型纳米载体抗癌药物控释研究进展。
IF 4.2
Therapeutic delivery Pub Date : 2023-09-01 Epub Date: 2023-10-25 DOI: 10.4155/tde-2023-0041
Baji Baba Shaik, Naresh Kumar Katari, Sreekanth B Jonnalagadda
{"title":"Internal stimuli-responsive nanocarriers for controlled anti-cancer drug release: a review.","authors":"Baji Baba Shaik, Naresh Kumar Katari, Sreekanth B Jonnalagadda","doi":"10.4155/tde-2023-0041","DOIUrl":"10.4155/tde-2023-0041","url":null,"abstract":"<p><p>Cancer disease is one of the most frequent life-threatening, with a high fatality rate worldwide. However, recent immunotherapy studies in various tumours have yielded unsatisfactory outcomes, with just a few individuals experiencing long-term responses. To overcome these issues, nowadays internal stimuli-responsive nanocarriers have been widely exploited to transport a wide range of active substances, including peptides, genes and medicines. These nanosystems could be chemically adjusted to produce target-based drug release at the target location, minimizing pathological and physiological difficulties while increasing therapeutic efficiency. This review highlights the various types of internal stimuli-responsive nanocarriers and applications in cancer diagnosis. This study can provide inspiration and impetus for exploiting more promising internal stimuli-responsive nanosystems for drug delivery.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"595-613"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50158833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intranasal nanoparticulate delivery systems for neurodegenerative disorders: a review. 神经退行性疾病的鼻内纳米颗粒递送系统：综述。
IF 4.2
Therapeutic delivery Pub Date : 2023-09-01 Epub Date: 2023-09-11 DOI: 10.4155/tde-2023-0019
Someshbabu Ramesh Babu, Harshith Hosahalli Shekara, Ashish Kumar Sahoo, Pyda Venkata Harsha Vardhan, Nitheesh Thiruppathi, Madhugiri Prakash Venkatesh
{"title":"Intranasal nanoparticulate delivery systems for neurodegenerative disorders: a review.","authors":"Someshbabu Ramesh Babu, Harshith Hosahalli Shekara, Ashish Kumar Sahoo, Pyda Venkata Harsha Vardhan, Nitheesh Thiruppathi, Madhugiri Prakash Venkatesh","doi":"10.4155/tde-2023-0019","DOIUrl":"10.4155/tde-2023-0019","url":null,"abstract":"<p><p>Neurodegenerative diseases are a significant cause of mortality worldwide, and the blood-brain barrier (BBB) poses a significant challenge for drug delivery. An intranasal route is a prominent approach among the various methods to bypass the BBB. There are different pathways involved in intranasal drug delivery. The drawbacks of this method include mucociliary clearance, enzymatic degradation and poor drug permeation. Novel nanoformulations and intranasal drug-delivery devices offer promising solutions to overcome these challenges. Nanoformulations include polymeric nanoparticles, lipid-based nanoparticles, microspheres, liposomes and noisomes. Additionally, intranasal devices could be utilized to enhance drug-delivery efficacy. Therefore, intranasal drug-delivery systems show potential for treating neurodegenerative diseases through trigeminal or olfactory pathways, which can significantly improve patient outcomes.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"571-594"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10570420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry update: the latest developments in the field of therapeutic delivery, July 2023. 行业更新：治疗递送领域的最新进展，2023年7月。
IF 4.2
Therapeutic delivery Pub Date : 2023-09-01 Epub Date: 2023-10-03 DOI: 10.4155/tde-2023-0085
Peter Timmins
{"title":"Industry update: the latest developments in the field of therapeutic delivery, July 2023.","authors":"Peter Timmins","doi":"10.4155/tde-2023-0085","DOIUrl":"10.4155/tde-2023-0085","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"527-541"},"PeriodicalIF":4.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41154746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bilosomes in brain drug delivery. 脑内药物输送中的胆汁体。
IF 4.2
Therapeutic delivery Pub Date : 2023-08-01 Epub Date: 2023-08-03 DOI: 10.4155/tde-2023-0049
Hemlata Kaurav, Deepak N Kapoor, Navneet Kumar Upadhyay
{"title":"Bilosomes in brain drug delivery.","authors":"Hemlata Kaurav,&nbsp;Deepak N Kapoor,&nbsp;Navneet Kumar Upadhyay","doi":"10.4155/tde-2023-0049","DOIUrl":"10.4155/tde-2023-0049","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 8","pages":"473-475"},"PeriodicalIF":4.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10603238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential role of herbal nanoformulations for skin disorders: a review. 草药纳米制剂对皮肤疾病的潜在作用：综述。
IF 4.2
Therapeutic delivery Pub Date : 2023-08-01 Epub Date: 2023-09-12 DOI: 10.4155/tde-2023-0024
Sahil Arora, Charul Rathore
{"title":"Potential role of herbal nanoformulations for skin disorders: a review.","authors":"Sahil Arora,&nbsp;Charul Rathore","doi":"10.4155/tde-2023-0024","DOIUrl":"10.4155/tde-2023-0024","url":null,"abstract":"<p><p><b>Aim:</b> In the recent advanced study, the popularity of herbal nano-formulation has gained around the whole world. As we know the reason behind it is that herbal products have comparatively lesser side effects than other synthetic products. <b>Significance:</b> These natural plant extracts have wide medicinal importance as they increase the overall bioavailability of products toward tissues. <b>Key findings:</b> This review provides the use of different herbal nano-formulations, their safety considerations, and the challenges being faced. It also highlights the various Clinical Trials and Patents that are published for skin disorders. <b>Conclusion:</b> The present review describes how the rise of herbal products has made wider interest in transdermal formulations and improve the overall productivity by preventing various skin disorders.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 8","pages":"511-525"},"PeriodicalIF":4.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10294472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry update, June 2023. 行业更新，2023年6月。
IF 4.2
Therapeutic delivery Pub Date : 2023-08-01 DOI: 10.4155/tde-2023-0068
Elaine Harris
{"title":"Industry update, June 2023.","authors":"Elaine Harris","doi":"10.4155/tde-2023-0068","DOIUrl":"https://doi.org/10.4155/tde-2023-0068","url":null,"abstract":"","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 8","pages":"477-484"},"PeriodicalIF":4.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10586114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment. 吸入宁替尼、吡非尼酮和马西坦治疗肺纤维化：一项实验室实验。
IF 4.2
Therapeutic delivery Pub Date : 2023-08-01 Epub Date: 2023-08-16 DOI: 10.4155/tde-2023-0045
Paul Zarogoulidis, Dimitris Petridis, Haidong Huang, Chong Bai, Panagoula Oikonomou, Christina Nikolaou, Dimitris Matthaios, Eleni-Isidora Perdikouri, Vasilis Papadopoulos, Savvas Petanidis, Christoforos Kosmidis, Charalampos Charalampidis, Wolfgang Hohenforst-Schmidt, Nikos Kougkas, Chrysanthi Sardeli
{"title":"Inhaled nintentanib, pirfenidone and macitentan for pulmonary fibrosis: a laboratory experiment.","authors":"Paul Zarogoulidis,&nbsp;Dimitris Petridis,&nbsp;Haidong Huang,&nbsp;Chong Bai,&nbsp;Panagoula Oikonomou,&nbsp;Christina Nikolaou,&nbsp;Dimitris Matthaios,&nbsp;Eleni-Isidora Perdikouri,&nbsp;Vasilis Papadopoulos,&nbsp;Savvas Petanidis,&nbsp;Christoforos Kosmidis,&nbsp;Charalampos Charalampidis,&nbsp;Wolfgang Hohenforst-Schmidt,&nbsp;Nikos Kougkas,&nbsp;Chrysanthi Sardeli","doi":"10.4155/tde-2023-0045","DOIUrl":"10.4155/tde-2023-0045","url":null,"abstract":"<p><p><b>Aim:</b> Idiopathic pulmonary fibrosis is a rare disease with few efficient drugs in the market. The consequences of this disease are mainly respiratory failure and pulmonary hypertension. <b>Materials & methods:</b> In our experiment we used the drugs pirfenidone, nintetanib and macitentan. We performed nebulization experiments with three jet nebulizers and three ultrasound nebulizers with different combinations of residual cup designs, and residual cup loadings in order to identify which combination produces droplets of less than 5 μm in mass median aerodynamic diameter. <b>Results:</b> Pirfenidone versus nintetanib had smaller droplet size formation at both inhaled technologies (1.37 < 2.23 and 1.92 < 3.11, jet and ultrasound respectively). <b>Discussion:</b> Pirfenidone and nintetanib can be administered as aerosol in any type of nebulization system.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 8","pages":"491-498"},"PeriodicalIF":4.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10603729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can Amphotericin B-mediated effects be limited using intranasal versus intravenous route? 两性霉素B介导的作用是否可以通过鼻内和静脉途径受到限制？
IF 4.2
Therapeutic delivery Pub Date : 2023-08-01 Epub Date: 2023-09-11 DOI: 10.4155/tde-2023-0032
Ruqaiyyah Siddiqui, Timothy Yu Yee Ong, Sutherland Maciver, Naveed Ahmed Khan
{"title":"Can Amphotericin B-mediated effects be limited using intranasal versus intravenous route?","authors":"Ruqaiyyah Siddiqui,&nbsp;Timothy Yu Yee Ong,&nbsp;Sutherland Maciver,&nbsp;Naveed Ahmed Khan","doi":"10.4155/tde-2023-0032","DOIUrl":"10.4155/tde-2023-0032","url":null,"abstract":"<p><p><b>Aim:</b> CNS infections due to parasites often prove fatal. In part, this is due to inefficacy of drugs to cross the blood-brain barrier. <b>Methods:</b> Here, we tested intranasal and intravenous route and compared adverse effects of Amphotericin B administration, through blood biochemistry, liver, kidney and brain histopathological evidence of toxicities <i>in vivo</i> post-administration. <b>Results:</b> It was observed that intranasal route limits the adverse side effects of Amphotericin B, in contrast to intravenous route. <b>Conclusion:</b> As parasites such as <i>Naegleria fowleri</i> exhibit unequivocal affinity toward the olfactory bulb and frontal lobe in the central nervous system, intranasal administration would directly reach amoebae bypassing the blood-brain barrier selectivity and achieve the minimum inhibitory concentration at the target site.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 8","pages":"485-490"},"PeriodicalIF":4.2,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10239587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ex vivo analysis of ketotifen content in an antihistamine-eluting contact lens worn up to 5 hours. 佩戴5小时的抗组胺洗脱隐形眼镜中酮替芬含量的体外分析。
IF 4.2
Therapeutic delivery Pub Date : 2023-07-01 DOI: 10.4155/tde-2023-0029
Brian Pall, Shivkumar Mahadevan, Azaam Alli, Frank Yi, Paul Gomes
{"title":"<i>Ex vivo</i> analysis of ketotifen content in an antihistamine-eluting contact lens worn up to 5 hours.","authors":"Brian Pall,&nbsp;Shivkumar Mahadevan,&nbsp;Azaam Alli,&nbsp;Frank Yi,&nbsp;Paul Gomes","doi":"10.4155/tde-2023-0029","DOIUrl":"https://doi.org/10.4155/tde-2023-0029","url":null,"abstract":"<p><p><b>Aim:</b> This study characterized <i>ex vivo</i> release of ketotifen from etafilcon A contact lenses worn over 5 h. <b>Materials & methods:</b> 14 participants, 21 to 59 years, wore lenses with 19 μg ketotifen over 8 visits, for 1 min to 5 h. Residual ketotifen was measured using high-performance liquid chromatography (HPLC) compared with unworn lenses from the same lots to determine percent ketotifen remaining. <b>Results:</b> Residual ketotifen ranged from 16.19 μg ± 0.44 (84.1%) [1 minute] to 0.20 μg ± 0.07 (1.1%) [5 h]. No adverse events or clinically significant biomicroscopy changes were observed. <b>Conclusion:</b> The ketotifen-releasing etafilcon A lenses were well-tolerated with an acceptable safety profile in the population studied. The release of ketotifen from study lenses over 5 h was consistent with a diffusion-controlled system.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":"14 7","pages":"407-417"},"PeriodicalIF":4.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10189953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信